OBJECTIVES: This study was conducted to examine the possibility of Carthami-Semen (CS, Safflower seed) acupuncture point injection as a new promising treatment for chronic daily headache (CDH). METHODS: A total of 40 subjects with CDH were recruited and randomised to a CS acupuncture point injection group or a normal saline (NS) acupuncture point injection group. Acupuncture point injections were applied twice a week during 4 weeks to the bilateral Fengchi (GB20), Jianjing (GB21) and Taiyang (EX-HN5) acupoints with CS extract or NS. OUTCOME MEASURES: The primary outcome measure was headache-related quality of life (QoL), assessed using the Headache Impact Test (HIT). Secondary outcome measures were the changes in the number of headache-free days and health status as assessed with the Short Form (36) Health Survey (SF-36). RESULTS:HIT scores decreased by 14.9 points in the CS acupuncture point injection group compared with 7.9 points in the NS acupuncture point injection group (p=0.013). Headache-free days increased by 32.6% in the CS acupuncture point injection group compared with 17.4% in the NS acupuncture point injection group (p=0.045). There were significant increases in SF-36 scores compared with baseline in both groups, but the mean improvement was greater in the CS acupuncture point injection group. No serious adverse events (AEs) were reported. CONCLUSIONS: We suggest that the CS acupuncture point injection could be a new safe and promising treatment for CDH. A larger and long-term follow-up trial is needed to determine more definitely the efficacy of CS acupuncture point injection and to elucidate how long the effect lasts.
RCT Entities:
OBJECTIVES: This study was conducted to examine the possibility of Carthami-Semen (CS, Safflower seed) acupuncture point injection as a new promising treatment for chronic daily headache (CDH). METHODS: A total of 40 subjects with CDH were recruited and randomised to a CS acupuncture point injection group or a normal saline (NS) acupuncture point injection group. Acupuncture point injections were applied twice a week during 4 weeks to the bilateral Fengchi (GB20), Jianjing (GB21) and Taiyang (EX-HN5) acupoints with CS extract or NS. OUTCOME MEASURES: The primary outcome measure was headache-related quality of life (QoL), assessed using the Headache Impact Test (HIT). Secondary outcome measures were the changes in the number of headache-free days and health status as assessed with the Short Form (36) Health Survey (SF-36). RESULTS:HIT scores decreased by 14.9 points in the CS acupuncture point injection group compared with 7.9 points in the NS acupuncture point injection group (p=0.013). Headache-free days increased by 32.6% in the CS acupuncture point injection group compared with 17.4% in the NS acupuncture point injection group (p=0.045). There were significant increases in SF-36 scores compared with baseline in both groups, but the mean improvement was greater in the CS acupuncture point injection group. No serious adverse events (AEs) were reported. CONCLUSIONS: We suggest that the CS acupuncture point injection could be a new safe and promising treatment for CDH. A larger and long-term follow-up trial is needed to determine more definitely the efficacy of CS acupuncture point injection and to elucidate how long the effect lasts.
Authors: Maria T Chao; Christine M Wade; Priscilla D Abercrombie; Denise Gomolak Journal: Altern Ther Health Med Date: 2014 Jan-Feb Impact factor: 1.305
Authors: Hans-Christoph Diener; David W Dodick; Peter J Goadsby; Richard B Lipton; Jes Olesen; Stephen D Silberstein Journal: Nat Rev Neurol Date: 2012-02-14 Impact factor: 42.937
Authors: C Wade; L Wang; W J Zhao; F Cardini; F Kronenberg; S Q Gui; Z Ying; N Q Zhao; M T Chao; J Yu Journal: BMJ Open Date: 2016-01-05 Impact factor: 2.692